368 related articles for article (PubMed ID: 21587223)
1. A decade in prostate cancer: from NMR to metabolomics.
DeFeo EM; Wu CL; McDougal WS; Cheng LL
Nat Rev Urol; 2011 May; 8(6):301-11. PubMed ID: 21587223
[TBL] [Abstract][Full Text] [Related]
2. In vivo MR spectroscopic imaging of the prostate, from application to interpretation.
Tayari N; Heerschap A; Scheenen TWJ; Kobus T
Anal Biochem; 2017 Jul; 529():158-170. PubMed ID: 28167072
[TBL] [Abstract][Full Text] [Related]
3. NMR-based metabolomics approach to target biomarkers for human prostate cancer.
Jordan KW; Cheng LL
Expert Rev Proteomics; 2007 Jun; 4(3):389-400. PubMed ID: 17552923
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance spectroscopic imaging: current status in the management of prostate cancer.
Nayyar R; Kumar R; Kumar V; Jagannathan NR; Gupta NP; Hemal AK
BJU Int; 2009 Jun; 103(12):1614-20. PubMed ID: 19338548
[TBL] [Abstract][Full Text] [Related]
5. NMR metabolomic profiles associated with long-term risk of prostate cancer.
Lécuyer L; Victor Bala A; Demidem A; Rossary A; Bouchemal N; Triba MN; Galan P; Hercberg S; Partula V; Srour B; Latino-Martel P; Kesse-Guyot E; Druesne-Pecollo N; Vasson MP; Deschasaux-Tanguy M; Savarin P; Touvier M
Metabolomics; 2021 Mar; 17(3):32. PubMed ID: 33704614
[TBL] [Abstract][Full Text] [Related]
6. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.
Kumar D; Gupta A; Nath K
Expert Rev Mol Diagn; 2016 Jun; 16(6):651-61. PubMed ID: 26959614
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of patients with and without prostate cancer using urine
Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
[TBL] [Abstract][Full Text] [Related]
8. Metabolite Analyses Using Nuclear Magnetic Resonance (NMR) Spectroscopy in Plasma of Patients with Prostate Cancer.
Ahmed D; Cacciatore S; Zerbini LF
Methods Mol Biol; 2023; 2675():195-204. PubMed ID: 37258765
[TBL] [Abstract][Full Text] [Related]
9. Spectroscopy in prostate cancer: hope or hype?
Roach M; Kurhanewicz J; Carroll P
Oncology (Williston Park); 2001 Nov; 15(11):1399-410; discussion 1415-6, 1418. PubMed ID: 11758871
[TBL] [Abstract][Full Text] [Related]
10. Application of metabolomics to prostate cancer.
Trock BJ
Urol Oncol; 2011; 29(5):572-81. PubMed ID: 21930089
[TBL] [Abstract][Full Text] [Related]
11. Hyperpolarized [1-
Scroggins BT; Matsuo M; White AO; Saito K; Munasinghe JP; Sourbier C; Yamamoto K; Diaz V; Takakusagi Y; Ichikawa K; Mitchell JB; Krishna MC; Citrin DE
Clin Cancer Res; 2018 Jul; 24(13):3137-3148. PubMed ID: 29599412
[No Abstract] [Full Text] [Related]
12. NMR-Based Prostate Cancer Metabolomics.
Euceda LR; Andersen MK; Tessem MB; Moestue SA; Grinde MT; Bathen TF
Methods Mol Biol; 2018; 1786():237-257. PubMed ID: 29786797
[TBL] [Abstract][Full Text] [Related]
13. [MR spectroscopic imaging for evaluation of prostate cancer].
Taouli B
J Radiol; 2006 Feb; 87(2 Pt 2):222-7. PubMed ID: 16484947
[TBL] [Abstract][Full Text] [Related]
14. Rapid nuclear magnetic resonance data acquisition with improved resolution and sensitivity for high-throughput metabolomic analysis.
Joseph D; Sukumaran S; Chandra K; Pudakalakatti SM; Dubey A; Singh A; Atreya HS
Magn Reson Chem; 2021 Mar; 59(3):300-314. PubMed ID: 33030750
[TBL] [Abstract][Full Text] [Related]
15. Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: Potential role in the diagnosis and management of prostate cancer.
Gholizadeh N; Pundavela J; Nagarajan R; Dona A; Quadrelli S; Biswas T; Greer PB; Ramadan S
Urol Oncol; 2020 Apr; 38(4):150-173. PubMed ID: 31937423
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging and spectroscopic imaging of prostate cancer.
Coakley FV; Qayyum A; Kurhanewicz J
J Urol; 2003 Dec; 170(6 Pt 2):S69-75; discussion S75-6. PubMed ID: 14610414
[TBL] [Abstract][Full Text] [Related]
17. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
Amsellem-Ouazana D; Younes P; Conquy S; Peyromaure M; Flam T; Debré B; Zerbib M
Eur Urol; 2005 May; 47(5):582-6. PubMed ID: 15826747
[TBL] [Abstract][Full Text] [Related]
18. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia.
Komoroski RA; Holder JC; Pappas AA; Finkbeiner AE
Magn Reson Med; 2011 Apr; 65(4):911-3. PubMed ID: 20967792
[TBL] [Abstract][Full Text] [Related]
19. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer.
Hricak H
Br J Radiol; 2005; 78 Spec No 2():S103-11. PubMed ID: 16306632
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
